<SEC-DOCUMENT>0001104659-20-058378.txt : 20200508
<SEC-HEADER>0001104659-20-058378.hdr.sgml : 20200508
<ACCEPTANCE-DATETIME>20200508070118
ACCESSION NUMBER:		0001104659-20-058378
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200508
DATE AS OF CHANGE:		20200508
EFFECTIVENESS DATE:		20200508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		20858609

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2019068d2_defa14.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 13pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-transform: uppercase; text-align: center">SCHEDULE
14A</P>

<P STYLE="font: bold 13pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: center">Proxy Statement Pursuant to Section
14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No. )</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Filed by the Registrant <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Check the appropriate box:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 92%; padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Preliminary Proxy Statement</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Definitive Proxy Statement</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></FONT></TD>
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Definitive Additional Materials</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Soliciting Material under &sect;240.14a-12</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: center"><FONT STYLE="font-size: 14pt"><B>Amicus Therapeutics,&nbsp;Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="padding-right: 4.5pt; padding-bottom: 12pt; padding-left: 0.05in; text-align: center">(Name of Registrant as Specified In Its Charter)</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="padding-right: 4.5pt; padding-bottom: 12pt; padding-left: 0.05in; text-align: center">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="3" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Payment of Filing Fee (Check the appropriate box):</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
<TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">No fee required.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%; padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="width: 6%; padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(1)</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 86%; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Title of each class of securities to which transaction applies:<BR> <U></U> &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(2)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Aggregate number of securities to which transaction applies:<BR> &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(3)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR> &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(4)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Proposed maximum aggregate value of transaction:<BR> &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(5)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Total fee paid:<BR> &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
<TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(1)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Amount Previously Paid:<BR> &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(2)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Form, Schedule or Registration Statement No.:<BR> &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(3)</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Filing Party:<BR> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">&nbsp;</TD>
<TD STYLE="padding-right: 4.5pt; padding-left: 0.05in; text-align: justify">(4) &nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; padding-right: 4.5pt; padding-left: 0.05in; text-align: left">Date Filed:<BR>&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2019068d2_defa14img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADDITIONAL INFORMATION REGARDING THE
ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, JUNE 4, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 24, 2020, Amicus Therapeutics, Inc. (the &ldquo;Company&rdquo;)
filed a definitive proxy statement with the Securities and Exchange Commission regarding its Annual Meeting of Stockholders (the
 &ldquo;Annual Meeting&rdquo;) to be held on Thursday, June 4, 2020. The following information supplements and relates to that proxy
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 8, 2020, the Company issued a press release announcing
that the Annual Meeting will be changed from an in-person meeting to a virtual format, conducted solely via live webcast, providing
information as to how stockholders can attend and participate in the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1.5pt solid"><B>THE
NOTICE SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amicus Therapeutics Announces Virtual
2020 Annual Meeting of Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CRANBURY, NJ, May 8, 2020</B> &ndash;
<U>Amicus Therapeutics</U> (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing
and delivering novel medicines for rare diseases, today announced that, its 2020 Annual Meeting of Stockholders will now be held
solely via live webcast due to the public health impact of the COVID-19 pandemic and out of an abundance of concern for the health
and wellbeing of our employees, stockholders and directors. As previously announced, the 2020 Annual Meeting will be held on June
4, 2020 at 9:00 am ET.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Attending the Virtual Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To attend and participate in the virtual
Annual Meeting of Stockholders, stockholders of record will need to visit <U>www.virtualshareholdermeeting.com/FOLD2020</U> and
use their 16-digit control number (the &ldquo;Control Number&rdquo;) received in their notice to log in to this website. Beneficial
owners of shares held in street name will need to follow the instructions provided by the broker, bank or other nominee that holds
their shares. Only one stockholder per Control Number can access the meeting. We would encourage stockholders to log in to this
website and access the webcast before the meeting&rsquo;s start time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Asking Questions and Voting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described in the proxy materials for
the Annual Meeting, Amicus stockholders as of the close of business on April 13, 2020 (the record date) are entitled to join the
live virtual meeting and shall be able to listen, vote, and submit questions remotely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proxy card included with the proxy
materials previously distributed on or about April 24, 2020 will not be updated to reflect the change in location and may continue
to be used to vote your shares in connection with the Annual Meeting. The Company encourages eligible shareholders to vote on the
proposals prior to the Annual Meeting using the instructions provided in the proxy materials previously distributed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Assistance with the Virtual Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further instructions on how to attend,
participate in and vote at the virtual Annual Meeting of Stockholders will be available at <U>www.virtualshareholdermeeting.com/FOLD2020.
</U>A support line will also be available on the meeting website on the day of the virtual Annual Meeting should stockholders
require assistance with logging in. Digital copies of the company&rsquo;s proxy statement and 2019 Annual Report are available
at <U>www.proxyvote.com.</U> These materials also are available on the Company&rsquo;s website at <U>https://ir.amicusrx.com/annual-reports-and-proxies.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About Amicus Therapeutics </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus Therapeutics (Nasdaq: FOLD) is
a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines
for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing
and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information
please visit the company&rsquo;s website at <U>www.amicusrx.com</U>, and follow on <U>Twitter</U> and <U>LinkedIn</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Forward-Looking Statements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Statements contained herein that relate
to the Company's 2020 Annual Meeting of Stockholders are forward-looking statements within the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as &quot;will be&quot;, &quot;will&quot;, &quot;may&quot; or other similar
words or expressions often identify forward-looking statements. Such statements are based on current expectations only, and are
subject to certain risks, uncertainties and assumptions, many of which are beyond our control. Among the factors that could cause
the Company&rsquo;s 2020 annual meeting logistical arrangements to change include: general business and economic conditions; imposition
of restrictive governmental regulations implemented to address public health concerns; or operational delays or difficulties because
of the novel coronavirus or similar diseases, or uncertainty regarding the same. We undertake no obligation to publicly update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Andrew Faughnan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>afaughnan@amicusrx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(609) 662-3809</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">FOLD&ndash;G</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2019068d2_defa14img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2019068d2_defa14img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !N 3L# 2(  A$! Q$!_\0
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ME%(#D4M?C!^QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!C_P#;;^'W[<OP]N/$7@'5);N*PG^RW]E=PFWO-/D(W*)(SGAEY5U+(V&
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M%/[#.EHWCOQ#Y>L7-N;FRT.PC^TZG?)E@"L0("*2K /*R(2K#=D8KYC\'_\
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M-LAB)[9QEFQV /;.,U]3?#C_ ()^>#O">)=:>[\1W.T#;*Q@MU/'(1#D_P#
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MWT7R_P A_P#P3R,WB3_@H7\()9 9IIO&^F7,F%SDB[21F_#!/X5_3+7\Y?\
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M2ZV5_O,GQSX#T3XG>%;O0O$FCZ9K^BWX47-AJ-JES;7 5@ZAXW!5L,JD9'4
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M(J5ZCJUG>3W9CA\/3H4U2HJT5L@HHHK$V"BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
